Shane Thomas Gleason Sells 7,073 Shares of InspireMD (NYSE:NSPR) Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 7,073 shares of InspireMD stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $2.51, for a total transaction of $17,753.23. Following the completion of the sale, the insider directly owned 1,109,733 shares of the company’s stock, valued at approximately $2,785,429.83. The trade was a 0.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The shares were sold at an average price of $1.01, for a total transaction of $23,005.78.

InspireMD Price Performance

Shares of NSPR stock traded up $0.03 on Thursday, hitting $1.03. The company’s stock had a trading volume of 160,140 shares, compared to its average volume of 182,457. InspireMD, Inc. has a fifty-two week low of $0.97 and a fifty-two week high of $2.93. The firm’s fifty day moving average price is $1.40 and its 200-day moving average price is $1.68. The stock has a market capitalization of $48.24 million, a price-to-earnings ratio of -1.37 and a beta of 0.82.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Ghisallo Capital Management LLC acquired a new position in InspireMD during the 3rd quarter worth $2,221,000. Aberdeen Group plc bought a new position in shares of InspireMD during the 3rd quarter worth about $5,979,000. Rosalind Advisors Inc. increased its holdings in shares of InspireMD by 70.6% during the 3rd quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock worth $9,413,000 after purchasing an additional 1,616,644 shares during the period. Virtu Financial LLC bought a new position in shares of InspireMD during the 4th quarter worth about $31,000. Finally, XTX Topco Ltd bought a new position in shares of InspireMD during the 4th quarter worth about $30,000. Institutional investors and hedge funds own 44.78% of the company’s stock.

Key Stories Impacting InspireMD

Here are the key news stories impacting InspireMD this week:

• Neutral Sentiment: Shane Thomas Gleason disclosed multiple recent sales of InspireMD shares, including transactions on May 19, May 23, May 27, May 29, May 30, and earlier January/February dates. Each filing says the sales were made to cover tax withholding obligations related to the vesting of equity awards, which makes the activity look more routine than a strategic exit. Article Title
• Neutral Sentiment: A new “Stock Forecast & Price Target” page for InspireMD may be contributing to increased trading interest, but the item itself does not include a specific rating change, earnings update, or business development that would clearly drive the shares. Article Title

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Maxim Group assumed coverage on shares of InspireMD in a research report on Monday, February 2nd. They set a “buy” rating and a $6.00 target price for the company. Lake Street Capital set a $4.00 target price on shares of InspireMD in a research report on Monday, May 4th. Piper Sandler reissued an “overweight” rating and set a $3.00 target price (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Finally, Loop Capital set a $5.00 target price on shares of InspireMD in a research report on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $4.50.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.